Locations
Conditions
Treatments
Institutions
Resources
For researchers
About us
Clinical trials
A Study of Invikafusp Alfa (STAR0602), a Selective T Cell Receptor (TCR)-Targeting, Bifunctional Antibody-fusion Molecule, in Combination With Sacituzumab Govitecan in Participants With Advanced Solid Tumors
Apply
Invikafusp Alfa & Sacituzumab Govitecan
A Study of Invikafusp Alfa (STAR0602), a Selective T Cell Receptor (TCR)-Targeting, Bifunctional Antibody-fusion Molecule, in Combination With Sacituzumab Govitecan in Participants With Advanced Solid Tumors
Basic information
Step 1/5
Provide your basic information
Age
ZIP code
Back
Next step